Aprinoia Therapeutics (Aprinoia Therapeutics) Change In Payables And Accrued Expense : $3.93 Mil (TTM As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Change In Payables And Accrued Expense?

Aprinoia Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2023 was $0.18 Mil. It means Aprinoia Therapeutics's Accounts Payable & Accrued Expense increased by $0.18 Mil from Dec. 2022 to Jun. 2023 .

Aprinoia Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2022 was $5.92 Mil. It means Aprinoia Therapeutics's Accounts Payable & Accrued Expense increased by $5.92 Mil from Dec. 2021 to Dec. 2022 .

Aprinoia Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Aprinoia Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Change In Payables And Accrued Expense Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Change In Payables And Accrued Expense

-0.85

5.92

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Change In Payables And Accrued Expense	-	2.17	3.75	0.18

Aprinoia Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $3.93 Mil.

Aprinoia Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines